tetano
Editor, Senior Moderator
CNS Neurosci Ther. 2018 Jul 25. doi: 10.1111/cns.13034. [Epub ahead of print]
[h=1]Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.[/h] Metze C[SUP]1[/SUP], Winkelmann A[SUP]1[/SUP], Loebermann M[SUP]2[/SUP], Hecker M[SUP]1[/SUP], Schweiger B[SUP]3[/SUP], Reisinger EC[SUP]2[/SUP], Zettl UK[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] To evaluate the immunogenicity and safety of a seasonal influenza vaccine in a cohort of multiple sclerosis (MS) patients receiving different immunomodulating/immunosuppressive therapies and assess predictors of immune response.
[h=4]METHODS:[/h] A prospective, multicenter, non-randomized observational study including 108 patients receiving a trivalent seasonal influenza vaccination was conducted. Influenza-specific antibody titers (H1N1, H3N2, and influenza B) were measured to evaluate rates of seroprotection and seroconversion/significant titer increase. Univariable and multivariable analyses were performed to identify prognostic factors of vaccination outcomes.
[h=4]RESULTS:[/h] Regarding the whole cohort, seroprotection rates >70% were achieved for each influenza strain. Interferon-treated patients reached high seroprotection rates (>84%). Good seroprotection rates were seen in patients treated with glatiramer acetate. In particular for H3N2, response rates were low in natalizumab-treated patients and in the small subgroup of fingolimod-treated patients. Patients with a previous disease-modifying therapy and a longer disease duration were less likely to respond sufficiently. No severe adverse events were reported. MS disease activity was not increased after a one-year follow-up period.
[h=4]CONCLUSION:[/h] Vaccination led to good immunogenicity, especially in MS patients treated with interferons and glatiramer acetate. At least for the H1N1 strain, rates of seroprotection and seroconversion/significant titer increase were high (>70% and >60%, respectively) for all therapeutic subgroups. Patients with a longer duration of the disease are exposed to an increased risk of insufficient immune response to vaccination.
? 2018 John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] disease-modifying therapy; immunogenicity; immunomodulation; influenza vaccine; multiple sclerosis
PMID: 30044050 DOI: 10.1111/cns.13034
[h=1]Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.[/h] Metze C[SUP]1[/SUP], Winkelmann A[SUP]1[/SUP], Loebermann M[SUP]2[/SUP], Hecker M[SUP]1[/SUP], Schweiger B[SUP]3[/SUP], Reisinger EC[SUP]2[/SUP], Zettl UK[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] To evaluate the immunogenicity and safety of a seasonal influenza vaccine in a cohort of multiple sclerosis (MS) patients receiving different immunomodulating/immunosuppressive therapies and assess predictors of immune response.
[h=4]METHODS:[/h] A prospective, multicenter, non-randomized observational study including 108 patients receiving a trivalent seasonal influenza vaccination was conducted. Influenza-specific antibody titers (H1N1, H3N2, and influenza B) were measured to evaluate rates of seroprotection and seroconversion/significant titer increase. Univariable and multivariable analyses were performed to identify prognostic factors of vaccination outcomes.
[h=4]RESULTS:[/h] Regarding the whole cohort, seroprotection rates >70% were achieved for each influenza strain. Interferon-treated patients reached high seroprotection rates (>84%). Good seroprotection rates were seen in patients treated with glatiramer acetate. In particular for H3N2, response rates were low in natalizumab-treated patients and in the small subgroup of fingolimod-treated patients. Patients with a previous disease-modifying therapy and a longer disease duration were less likely to respond sufficiently. No severe adverse events were reported. MS disease activity was not increased after a one-year follow-up period.
[h=4]CONCLUSION:[/h] Vaccination led to good immunogenicity, especially in MS patients treated with interferons and glatiramer acetate. At least for the H1N1 strain, rates of seroprotection and seroconversion/significant titer increase were high (>70% and >60%, respectively) for all therapeutic subgroups. Patients with a longer duration of the disease are exposed to an increased risk of insufficient immune response to vaccination.
? 2018 John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] disease-modifying therapy; immunogenicity; immunomodulation; influenza vaccine; multiple sclerosis
PMID: 30044050 DOI: 10.1111/cns.13034